(S) -JDQ-443

JDQ-443 is a selective, covalent, and orally bioavailable inhibitor targeting the KRAS G12C mutation. Its (S) -isomer form exhibits potent antitumor activity, as demonstrated in both cellular assays and in vivo preclinical models for oncology research.